Peptides for Menopause and PCOS: Research & Support

Menopause, perimenopause, and PCOS bring real physiological changes – not just symptoms to “push through.” Energy levels, metabolism, recovery, mood, and even skin quality can shift in ways that are hard to predict and even harder to explain to someone who hasn’t experienced them. This is why there’s growing interest in peptides for menopause and PCOS – small signalling molecules that researchers are studying for their potential to influence key processes in the body.

This isn’t about miracle cures or “anti-ageing” slogans. It’s about looking at the biology, understanding what’s changing, and exploring whether targeted compounds might one day help address those changes. Where evidence exists, we’ll show you. Where it’s still early days, we’ll say so. For general background on these conditions, see the NHS menopause guide and the NHS PCOS guide.

Energy, Metabolism & Body Composition

After menopause, falling oestrogen levels change how fat is stored, shifting from hips and thighs to the abdomen. This increase in visceral fat (VAT) raises the risk of insulin resistance and cardiovascular disease. In PCOS, insulin resistance is already more common, and abdominal fat can be harder to shift. At the same time, muscle mass tends to decline with age, and mitochondrial efficiency – the way cells produce energy – can decrease, leaving many women feeling less energetic.

Researchers are interested in whether certain peptides can support healthier fat distribution, preserve lean muscle, and improve metabolic flexibility during these stages.

Tesamorelin

Mechanism: A synthetic analogue of growth hormone–releasing hormone (GHRH) that stimulates the pituitary to release GH, raising IGF-1 levels. This promotes fat breakdown (lipolysis) and can preferentially target visceral adipose tissue.

Evidence: Multiple randomised controlled trials in people with HIV-associated lipodystrophy have shown 8–15% reductions in VAT over 26–52 weeks, with preservation of lean mass and some improvements in liver fat. While these trials weren’t in menopausal or PCOS populations, the mechanism – reducing metabolically harmful VAT – is directly relevant.

Caveats: Most data come from a specific patient group. Trials in healthy midlife women or PCOS populations are still needed.

Read more: Tesamorelin overview

MOTS-c

Mechanism: A peptide encoded in the mitochondrial genome, released under metabolic stress. It activates AMPK, improving glucose uptake, fatty acid oxidation, and cellular energy production.

Evidence: In animal studies, MOTS-c improves exercise capacity, reduces weight gain on high-fat diets, and enhances insulin sensitivity. Observational human data link lower MOTS-c levels to metabolic disorders.

Caveats: Human intervention data are sparse. It’s an intriguing area of metabolic research but not yet established in menopausal or PCOS-specific contexts.

Read more: MOTS-c overview

Inflammation, Recovery & Tissue Repair

Joint aches, slower healing, and more lingering inflammation after training are common complaints in both menopause and PCOS. Declining oestrogen can affect collagen production and tissue elasticity, while chronic low-grade inflammation is more prevalent in insulin-resistant states. This combination can leave recovery slower and niggles more persistent.

Peptides in this category are being explored for their potential to support tissue repair, modulate inflammation, and promote healthier connective tissue.

BPC-157

Mechanism: A synthetic fragment of a protein found in gastric juice, BPC-157 is studied for its role in angiogenesis (new blood vessel formation) and tissue regeneration, as well as its potential anti-inflammatory effects.

Evidence: Preclinical studies show accelerated tendon, ligament, muscle, and nerve healing, with improved tissue organisation and reduced inflammatory markers. Human data are limited and mostly anecdotal.

Read more: BPC-157

TB-500

Mechanism: A synthetic fragment of thymosin beta-4, involved in cell migration, angiogenesis, and actin regulation – key processes in wound healing.

Evidence: Human trials for thymosin beta-4 have shown benefits in corneal healing. Musculoskeletal and systemic data come mainly from animal models, suggesting potential in soft-tissue repair.

Read more: TB-500

KPV

Mechanism: A tripeptide derived from alpha-MSH, studied for its ability to reduce inflammation via the melanocortin pathway, particularly in epithelial tissues like skin and gut.

Evidence: In animal models, KPV reduces inflammation in colitis and dermatitis, with targeted uptake into inflamed tissue. Human studies are limited.

Read more: KPV

GHK-Cu

Evidence: Multiple human dermatology studies show improvements in skin thickness, elasticity, and repair markers after GHK-Cu application. Its relevance here is in supporting connective tissue health as well as skin quality.

Read more: GHK-Cu

Mood, Focus & Cognitive Resilience

Hormonal changes can influence neurotransmitter systems, affecting mood stability, stress response, and cognitive performance. Many women in menopause or with PCOS report “brain fog,” difficulty concentrating, or heightened anxiety. This isn’t imagined – it’s linked to real biochemical shifts.

Researchers are exploring whether certain neuroactive peptides can modulate neurotransmitters and neurotrophic factors to support clearer thinking and emotional balance.

Selank

Mechanism: An anxiolytic peptide studied for its modulation of the GABAergic system and potential to enhance resilience to stress.

Evidence: Small human studies (mainly from Russian research) suggest reductions in anxiety and improvements in cognitive performance under stress. Western large-scale trials are lacking.

Read more: Selank

Semax

Mechanism: A peptide fragment derived from ACTH, with reported effects on neurotrophic factor expression and cerebral blood flow regulation.

Evidence: Preclinical and limited clinical studies suggest benefits in recovery from brain injury and in cognitive tasks. More robust trials are needed to confirm effects in healthy adults or hormonal transition states.

Read more: Semax

Sleep Quality & Mitochondrial Function

Unrefreshing sleep and daytime fatigue are common during menopause and in PCOS, often linked to both hormonal shifts and mitochondrial inefficiency. Mitochondria are the “power plants” of cells – if they aren’t functioning optimally, energy levels drop, even if sleep duration is adequate.

SS-31 (Elamipretide)

Mechanism: A mitochondria-targeted peptide that binds cardiolipin in the inner mitochondrial membrane, helping stabilise the electron transport chain and improve ATP production.

Evidence: Animal studies show improved exercise tolerance and mitochondrial efficiency with SS-31. Early human trials in various conditions suggest improved bioenergetics, though results vary by indication.

Read more: SS-31

Key Takeaways

• Menopause and PCOS involve genuine metabolic, inflammatory, and neurological shifts – not just “getting older” or “being hormonal.”
• Peptide research is still emerging in these areas, with some compounds supported by strong mechanistic rationale and others backed mainly by early-stage or indirect evidence.
• Evidence quality varies; what’s promising in one context may not yet be proven in menopausal or PCOS populations.

We’ll keep tracking the research and publishing plain-English summaries on our Biohacking page so you can follow the science as it develops.

Educational only: This article summarises areas of scientific research and is not medical advice. Peptides from River Peptides are supplied strictly for laboratory research use only, not for human consumption or therapeutic use.